FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Fluidigm Corporation Receives CE-IVD Mark for Its Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19”
Fluidigm Corporation (NASDAQ: FLDM) surged just over 15% in premarket trading after receiving the CE-IVD mark for its Advanta™ Dx SARS-CoV-2 RT-PCR Assay.
The assay is an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV-2 virus and the company’s clinical studies for submission demonstrated 100% agreement between saliva results from the Advanta Dx Assay and results from paired nasopharyngeal samples tested with authorized assays.
Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.
For more information, please visit: Fluidigm Corporation
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.